Effects of dialyzed membrane on TGF-β1 and MCP-1 plasma levels in hemodialysis patients
gU Yong,WU Yonggui,ZHOU Jianghua(Division of Nephrology, Huashan Hospital, Shanghai Medical University, Shanghai 200040, China)
Abstract:Objective To investigate effects of different dialyzed membrane on transforming growth factor(TGF-β1) and monocyte chemoattractant protein(MCP-1) plasma levels in maintenance hemodialysis(MHD) patients. Methods The plasma concentrations of TGF-β1 and MCP-1 were measured by ELISA assay in well-matched uremic patients undergoing maintenance hemodialysis with either cuprophane (CU, n=27) or polysulfone(PSU, n=25). Results Compared with controls (50.2±5.7 ng/ml), the patients on CU (82.9±9.8 ng/ml) and PSU (65.5±6.5 ng/ml)membranes dialysis had significantly higher mean TGF-β1 concentration (P<0.01, P<0.05) . However, the patients on PSU membrane dialysis had significantly lower mean TGF-β1 concentrations in contrast with CU membrane dialysis. MCP-1 plasma levels were also higher in patients dialyzed with PSU(72.2±5.3 pg/ml) than in controls(56.4±7.8) . In contrast to TGF-β1, the increase was greater in pSU-treated patients than in CU-theated patients. In addition, negative correlation was observed between the plasma levels of TGF-β1 and MCP-1 in patients dialyzed with CU or pSU. Conclusions MHD is associated with the increase of plasma levels of TGF-β1 and MCP-1. Moreover, the type of dialysis membrane has different effects on plasma levels of TGF-β1 and MCP-1.
Keywords:Dialyzed membrane; Transforming growth factor; Monocyte chemoattractant protein参考文献:
[1]Massague J. Transforming growth factor-β family. Annu Rev, 1990, 6: 597-640.
[2]Anderson J, Briefel G, Jones JM, et al. Effect of acetate dialysate on transforming growth factor-β1, interleukin, and β2-microglohulin plasma levels. Kindey Int, 1991, 40: 1100-1117.
[3]Jiang X, Kanai H, Shigehara T, et al. Metabolism of transforming growth factor-β in patients receiving hemodialysis especially those with renal osteodystrophy. Renal Failure, 1998, 20: 135-145.
[4]Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein levels in patients with glomerular disease. Am J Kidney dis, 1996, 27: 640-646.
[5]Chantry D, Turner M, Abrey E, et al. Modulation of cytokine production transforming growth factor β ?J immunol, 1989, 142: 4295-4300.
[6]Shull MM. Ormsbv I. Kier AB. et al. Tareeted disruntion of the mouse transforming growth factor β1 gene results in multifocal inflammatory disease. Nature, 1992. 359: 692-699.
[7]Mege JL, Capo C, Purgus R, et al. Monocyte production of transforming growth factor β in long-term hemodialysis: modulation by hemodialysis membranes. Am J Kidney Dis, 1996, 28: 395-399.
[8]Schindler R, Lonnemann G, Shaldon S, et al. Transcription not synthesis of interleukin 1 and tumor necrosis factor by complement. Kidney int, 1990, 37;85-93.
[9]Welch GR, Wong HL, Wahl SM, et al. Selective induction of FcRIII on human monocytes by transforming growth factor β. J immunol, 1990, 144: 3444-3448.
收稿日期:1999-08-20
